title: That's how you make drugs!
abstract: Although the science is able to proof that a drug works for the BRCA mutation in breast cancer, prostate cancer and pancreatic cancer (and maybe in other BRCA-mutated cancers) we stick to the registration path of doing phase 1, 2 and 3 trials based on organs. With the knowledge of today and the practice of personalized medicine we are able to give the drug olaparib much faster and save lives or at least extend lives with a good quality of life. This can be done differently if patients are involved in the process of determining the research, designing the trials and organizing the trials. If done properly we help patients in the first place and all the stakeholders will benefit as well.
authors.affiliation: CEO & Patient Advocate, Inspire2Live, Amsterdam, The Netherland. peter.kapitein@gmail.com.
authors.forename: Peter
authors.initials: P
authors.lastname: Kapitein
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000379:methods*; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010344:Patient Advocacy; D018802:Patient-Centered Care; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents
keywords: Patient advocacy; drug design; patient centered research; registration; trial design